- Home
- MGRM vs VIGL Comparison
MGRM vs VIGL Comparison
Compare MGRM & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRM
- VIGL
- Stock Information
- Founded
- MGRM 2016
- VIGL 2020
- Country
- MGRM United States
- VIGL United States
- Employees
- MGRM N/A
- VIGL N/A
- Industry
- MGRM Medical/Dental Instruments
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- MGRM Health Care
- VIGL Health Care
- Exchange
- MGRM Nasdaq
- VIGL Nasdaq
- Market Cap
- MGRM 79.9M
- VIGL 89.3M
- IPO Year
- MGRM N/A
- VIGL 2022
- Fundamental
- Price
- MGRM $2.94
- VIGL $1.78
- Analyst Decision
- MGRM Strong Buy
- VIGL Strong Buy
- Analyst Count
- MGRM 1
- VIGL 5
- Target Price
- MGRM $5.40
- VIGL $16.33
- AVG Volume (30 Days)
- MGRM 1.9M
- VIGL 163.8K
- Earning Date
- MGRM 03-12-2025
- VIGL 03-13-2025
- Dividend Yield
- MGRM N/A
- VIGL N/A
- EPS Growth
- MGRM N/A
- VIGL N/A
- EPS
- MGRM N/A
- VIGL N/A
- Revenue
- MGRM N/A
- VIGL N/A
- Revenue This Year
- MGRM N/A
- VIGL N/A
- Revenue Next Year
- MGRM $636.34
- VIGL N/A
- P/E Ratio
- MGRM N/A
- VIGL N/A
- Revenue Growth
- MGRM N/A
- VIGL N/A
- 52 Week Low
- MGRM $1.82
- VIGL $1.49
- 52 Week High
- MGRM $4.90
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- MGRM 53.97
- VIGL 35.03
- Support Level
- MGRM $2.79
- VIGL $1.74
- Resistance Level
- MGRM $3.08
- VIGL $1.94
- Average True Range (ATR)
- MGRM 0.36
- VIGL 0.16
- MACD
- MGRM -0.00
- VIGL -0.02
- Stochastic Oscillator
- MGRM 38.14
- VIGL 16.90
About MGRM Monogram Orthopaedics Inc.
Monogram Technologies Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.